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Abstract Neutrophil granulocytes are important mediators
of innate immunity, but also participate in the pathogenesis of
(auto)inflammatory diseases. Neutrophils express a specific
set of proteolytic enzymes, the neutrophil serine proteases
(NSPs), which are stored in cytoplasmic granules and can be
secreted into the extra- and pericellular space upon cellular
activation. These NSPs, namely cathepsin G (CG), neutrophil
elastase (NE), and proteinase 3 (PR3), have early been
implicated in bacterial defense. However, NSPs also regulate
the inflammatory response by specifically altering the
function of cytokines and chemokines. For instance, PR3
and NE both inactivate the anti-inflammatory mediator
progranulin, which may play a role in chronic inflammation.
Here, we provide a concise update on NSPs as modulators of
inflammation and discuss the biological and pathological
significance of this novel function of NSPs. Mounting
evidence support an important proinflammatory function for
PR3, which may have been underestimated in the past.
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Introduction
Neutrophil granulocytes make up the majority of all
leukocytes in peripheral, human blood, where they circulate
through the body and swiftly react on danger signals from
injured or infected tissues. Once infection or wounding
occurs, neutrophils are one of the first cell types that
infiltrate the harmed tissue, where they release antimicro-
bial factors and reactive oxygen species (ROS) to kill
pathogens and disinfect the injured tissue. Neutrophils
contribute to inflammation and bacterial defense mainly
via three distinct cell biological mechanisms, namely by
phagocytosis, degranulation or the formation of neutrophil
extracellular traps (NETs) [1]. Bacterial infections are
usually battled via phagocytosis of the pathogens, i.e., the
receptor-mediated uptake of bacteria followed by degrada-
tion of the pathogen inside the phagolysosome. Neutrophils
are pre-charged with antimicrobial factors such as neutro-
phil serine proteases (NSPs), which are stored in cytoplas-
mic organelles, the so-called azurophilic granules, ready to
be released into the extracellular space by degranulation.
When neutrophils encounter bacteria, they can also undergo
an alternative cell death program leading to the extrusion of
their own nuclear chromatin to form NETs, extracellular
chromatin fibers decorated with antimicrobial proteases that
trap and kill bacteria even after neutrophil cell death [2].
However, uncontrolled neutrophil activation can lead to
chronic inflammatory conditions such as autoimmune
diseases or hypersensitivity reactions. For instance, neutro-
phil activation by autoantibodies in autoimmune small-
vessel vasculitis promotes the formation of NETs, which
are deposited in the kidneys of these patients and are likely
to drive the disease process and the autoimmune response
against myeloperoxidase and PR3 present on these NETs
[3]. Recent studies have clarified that the physiological role
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DOI 10.1007/s00109-010-0677-3of NSPs is not limited to the degradation of microbes, but
also involves specific immunoregulatory functions that
affect the cascade of events during the inflammatory
reaction [4]. In this minireview, we provide a concise
update on the role of NSPs as inflammatory mediators and
discuss the biological and pathological significance of these
events.
Neutrophil serine proteases
Neutrophils express several classes of proteases including
matrix metalloproteinases such as matrix metalloproteinase
(MMP)-8 and -9, cysteine proteases such as caspases or
calpain, and NSPs. Serine proteases are a class of proteases
with the amino acid serine as the key residue of their
enzymatic center, which initiates the proteolytic cleavage of
specific target proteins, the protease substrates. The serine
proteases of neutrophils cathepsin G (CG), neutrophilelastase
(NE), and proteinase 3 (PR3) are crucially involved in
bacterial defense [5], but also mediate regulatory functions
that shape the inflammatory response [4]. While PR3 and
NE are very similar in their substrate specificity supporting a
potentially redundant function for these enzymes, CG
usually targets a different set of substrate proteins.
Unregulated extracellular proteolysis would be detrimental
to the entire organism. Hence, the liver constantly produces
copious amounts of physiological serine protease inhibitors,
such as α1-antitrypsin (α1-AT), α1-antichymotrypsin, and
α2-macroglobulin, which are distributed throughout the body
in the plasma and interstitial fluids and efficiently remove
NSPs and other proteases after their release by complexation
and delivery to lysosomes of phagocytic cells. Moreover,
there are tissue specific inhibitors of NSPs such as elafin or
secretory leukocyte protease inhibitor (SLPI), which control
serine protease activity in interstitial fluids. Disruption of the
balance between protease and their inhibitors as it occurs in
patients with genetic α1-AT deficiency leads to the develop-
ment of lung emphysema and certain autoimmune disorders
[6]. This reflects the involvement of NSPs in the progression
of inflammatory conditions and tissue breakdown.
NSPs control inflammatory reactions
The role of NSPs in inflammation has been controversial
for several years. Most knowledge about the function of
NSPs has been gained from in vitro studies using purified
enzymes. Initial findings that NSPs cleave extracellular
matrix components suggested that these enzymes might
facilitate the egress of leukocytes from blood vessels and
pave the way towards the sites of inflammation. More
recent reports have provided interesting in vitro results
showing that NSPs cleave several chemokines and cytokines,
which leads to enhancement or abolishment of the function of
these immune mediators [7, 8]. Some of these studies
analyzed ex vivo specimens by comparing chemokine or
cytokine cleavage in specimens from patients suffering from
inflammatory conditions with those from healthy control
individuals (summarized in Supplementary Table 1). How-
ever, the biological significance of these data remains to be
addressed using adequate experimental in vivo models in
order to elucidate if a substrate is in fact targeted by the
protease under physiological conditions.
The recent generation of NSP-deficient mice has formed
the basis for the in vivo evaluation of the role of these
proteases during inflammation. For instance, NE-deficient
animals have been used to determine whether this enzyme
is critical for neutrophil extravasation during inflammation
as suggested by previous in vitro results. However, these
papers have yielded conflicting results regarding the effect of
NE-deficiency on neutrophil extravasation to sites of inflam-
mation, since NE may or may not be important for leukocyte
migration across the basement membrane [9, 10]. One of the
first in vivo findings that supported an immunoregulatory role
of NSPs were made in mice deficient in dipeptidyl peptidase I
(DPPI), another protease that mediates the conversion of
NSPs from their inactive precursors (zymogen) into the
enzymatically active protease by removal of an N-terminal
pro-peptide [11]. Neutrophils of DPPI-deficient mice showed
very little NSP enzymatic activity and demonstrated strongly
decreased infiltration to the sites of inflammation in an
experimental arthritis model, although neutrophil migration in
vivo appeared generally normal in these mice. Of importance,
this was accompanied by decreased local production of
inflammatory cytokines. These findings suggest that NSPs
modulate cellular events such as neutrophil activation and
chemokine production, while at least in this setting they are
not directly necessary for the crossing of the endothelial
basement membrane during neutrophil diapedesis.
Cellular activation of neutrophil granulocytes during the
inflammatory response leads to the substantial release of
NSPs into the extracellular space, where the proteolytic
activity of these enzymes is tightly regulated by local
protease inhibitors (Fig. 1a). There are several ways how
NSPs can be active despite the presence of protease
inhibitors. For instance, previous studies have revealed that
NSPs compartmentalize to the cell surface of neutrophils
where they may be shielded from inhibitor binding and
therefore fully active [12]. NSPs are also present on
extracellular chromatin fibers called NETs [2, 3]. It remains
to be determined whether NSPs on NETs are enzymatically
active and whether their interaction with endogenous
inhibitors is altered. Moreover, inhibitors of NSPs can be
degraded by other proteases released from activated
neutrophils such as MMP-9, which degrades the serpin
24 J Mol Med (2011) 89:23–28α1-PI and thus prolongs local NE proteolytic activity [13].
Hence, the pericellular microenvironment around a neutrophil
may be depleted from local inhibitors leading to increased
NSP activity at the site of inflammation.
But how do NSPs regulate the course of an inflammatory
response on the molecular level? In the following parts, we
will highlight selected actions that involve NSP function
during the inflammatory response.
Regulation of chemokine function
The coordination of leukocyte migration to a damaged
tissue is essentially mediated by a concentration gradient of
chemokines, which is sensed by the migrating cell using G
protein-coupled receptors. Extracellular proteases modulate
chemokine function in several ways, which may lead to
abrogation or enhancement of chemokine function, and
sometimes alters the bioavailability of the chemokine.
Proteolytic abrogation of chemokine function often leads
to an inflammation-dampening effect or changes the
subsequent recruitment of immune cells. The stroma-
derived factor 1α (SDF-1α) is an important lymphocyte-
attracting chemokine. The proteolytic cleavage of SDF-1α
by NE on the endothelium during neutrophil extravasation
inactivates the chemokine and leads to decreased secondary
recruitment of lymphocytes to the site of inflammation.
Fig. 1 NSPs regulate inflamma-
tory processes via multiple
pathways. a Neutrophil activa-
tion by proinflammatory stimuli
lead to increased externalization
of NSPs. Activated neutrophils
(red) release NSPs by degranu-
lation, or formation of NETs.
Certain fractions of NSPs are
compartmentalized to cell
surface receptors and stay in the
pericellular environment. The
function of NSPs is controlled
by the balance between
proteases and protease inhibitors
circulating in blood and intersti-
tial fluids. b Extracellular PR3
converts IL-8 released from
neutrophils and endothelial cells
by N-terminal truncation
(cleavage sequence is indicated)
into a more bioactive
chemokine. This may potently
enhance the recruitment of
further neutrophils to the site of
inflammation. c PR3 acts as a
converting enzyme of pro-
TNFα, the membrane-attached
precursor of the potent proin-
flammatory cytokine TNFα.
This may be a crucial step in the
establishment of an inflammatory
milieu. d Neutrophils
extravasating from the vascula-
ture are initially controlled by
anti-inflammatory PGRN. PR3
and NE cooperatively enhance
neutrophil activation by specifi-
cally degrading inflammation-
suppressing PGRN. e CG
interacts with surface integrins
during the adhesion of
neutrophils to immobilized
immune complexes, where it
promotes integrin clustering,
cytoskeletal rearrangements, and
subsequently the release of
neutrophil attracting chemokines
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important step that controls the temporal pattern of immune
cell trafficking to inflammatory sites [14].
A common mechanism of chemokine alteration that
frequently involves NSP function is the proteolytic trunca-
tion at the N-terminus of the chemokine. In many cases,
this removes several amino acids N-terminal to the
chemotactic motif without destroying its biological func-
tion, but rather leading to enhanced chemotactic potential of
the molecule [8]. Interleukin 8 (IL-8) is one prominent
neutrophil-attracting chemokine that is cleaved by all three
members of NSPs with differential effects on its biological
function. Interestingly, while CG and NE mediated N-
terminal truncation of IL-8 leads to inactivation of the
chemokine, PR3 proteolytically converts IL-8 into a more
potent neutrophil activating version [15]. This may have
important implications during the recruitment of inflamma-
tory cells to the site of inflammation (Fig. 1b). However,
the biological significance of this proteolytic conversion of
chemokines remains to be evaluated in vivo. While there is
no direct homolog of IL-8 in mice, the respective IL-
8 receptor homolog is known to be activated strongest by
macrophage inflammatory protein 2 (MIP-2), and by the
approximately tenfold less potent chemokine KC [16].
Hence, analyzing the cleavage of MIP-2 and KC in mice,
for instance in NSP-depleted mice, will provide a useful
tool to address the biological significance of proteolytic
modulation of IL-8.
Conversion of inflammatory mediators
The posttranslational conversion of cytokine precursors by
extracellular proteases determines the activation of cyto-
kines and the time frame of their activity. For instance, all
three members of the NSPs have been shown to inactivate
the soluble IL-6 receptor, thus interfering with IL-6
signaling, which may contribute to the inflammatory
condition in patients suffering from cystic fibrosis [17].
Another key proinflammatory mediator is tumor necrosis
factor α (TNFα) that is produced as a membrane-attached
precursor and activated by proteolytic conversion after
which the active form of TNFα is solubilized. This is
mostly carried out by a metalloproteinase, named TNFα-
converting enzyme (TACE, ADAM17) [18]. Interestingly,
also PR3 seems to contribute to TNFα conversion for
example in pneumonia, as indicated by experiments using
alveolar macrophages, which, although they show no
expression of PR3, seem to carry significant amounts of
PR3 on their cell surface [19]. This might be an important
function of PR3 during the establishment of an inflamma-
tory milieu (Fig. 1c). Moreover, PR3 proteolytically
activates further inflammatory cytokines including IL-1β
[20], IL-18 [21], as well as IL-32, a recently discovered
cytokine that may play a crucial role during lung inflamma-
tion by triggering the release of neutrophil-attracting IL-
8 from epithelial cells [22]. Although caspase-1 is probably
the most important IL-1β-activating protease, results from
DPPI-deficient mice, which lack NSP enzymatic activity,
argue for an important role of PR3 in the conversion of this
potent inflammatory mediator in a mouse model for
rheumatoid arthritis [23]. The fact that all these cytokines
areselectivelyconvertedbyPR3,butnotbyCGorNE,points
towards a distinct proinflammatory role of PR3 during the
establishment of an inflammatory environment. However,
these findings are mainly based on in vitro studies and remain
to be corroborated by in vivo experiments to determine the
biological relevance of PR3-mediated conversion of these
cytokines.
Progranulin (PGRN; also known as granulin-epithelin
precursor) is an important regulator of the wound-healing
response [24]. Zhu and co-workers have described that
PGRN potently suppresses the adhesion-dependent oxida-
tive burst and release of proteases by neutrophils in the
presence TNFα, however, it loses its anti-inflammatory
activity after cleavage by NE [25]. Recent studies using
PR3/NE double-deficient mice revealed that PGRN is
degraded by both PR3 and NE during neutrophil activation
in vitro and immune complex-mediated inflammation in
vivo [26]. In the absence of PR3 and NE, anti-inflammatory
PGRN was not degraded any more leading to significantly
higher PGRN levels during the inflammatory response.
This may inhibit the activation of infiltrating neutrophils
and most likely leads to significantly decreased feedback
recruitment of inflammatory cells, which explains the
impaired inflammatory response to immune complex
deposition in PR3/NE-deficient mice (Fig. 1d). This
mechanism may play an important role in the establishment
and control of the chronic inflammation. Interestingly, loss-
of-function mutations in the PGRN gene are associated with
the development of neurodegenerative disorders such as
dementia, Alzheimer, and Parkinson disease [27]. Indeed,
recent studies using PGRN-deficient mice suggest that
decreased levels of PGRN in these patients leads to a
chronic, subtle inflammatory condition, which may finally
manifest in age-related neurodegenerative disease [28]. The
details about the exact molecular pathway of the anti-
inflammatory effects linked with PGRN yet remains to be
elucidated.
NSPs engage surface receptors
As mentioned earlier, NSPs often bind to surface receptors,
once they are externalized by activated neutrophils. This
can create an auto- or paracrine effect, since several
receptors transduce signals that promote neutrophil activa-
tion or alter epithelial cell function. For instance, CG
26 J Mol Med (2011) 89:23–28appears to trigger integrin clustering on neutrophils inter-
acting with immobilized immune complexes, which leads
to cytoskeletal rearrangements, increased ROS production,
and secretion of chemokines such as MIP-2 [29]. These
findings suggest an important role of CG during immune
complex-induced inflammation (Fig. 1e). However, the
exact molecular mechanism as to how CG modulates
integrin clustering on the cell surface remains elusive.
Another intriguing pathway of NSP-mediated inflamma-
tion is based on the engagement of protease-activated
receptors (PARs), which are G protein-coupled receptors
mostly expressed on platelets and epithelial cells that are
activated by proteolytic cleavage of the extracellular domain.
All three NSPs have been implicated in activating PAR-2 on
human oral epithelial cells and gingival fibroblasts, which
resulted in the release of proinflammatory mediators such as
IL-8 [30], suggesting that PAR-activation by NSPs may
contribute to the inflammatory process for example during
peridontitis. Moreover, NE and PR3, but not CG, seem to be
involved in activating PAR-1 and PAR-2 on epithelial cells
leading to downregulation of epithelial barrier function and
increased leukocyte transmigration, a process that may be
important in the pathogenesis of inflammatory bowel disease
[31]. Although NSPs may be important activators of PARs,
many aspects of this relationship remain elusive. Here again,
most findings are based on in vitro studies and would require
further confirmation in the living animal. For instance, PAR-2
is known to be expressed on neutrophils, however, it is still
unclear whether NSPs externalized by stimulated neutrophils
promote an autocrine feedback on neutrophil activation via
PAR-2.
The toll-like receptors (TLRs) represent another class of
intra- and extracellular membrane-anchored molecules that
sense inflammatory stimuli such as bacterial DNA or
lipopolysaccharide (LPS) and mediate cellular activation via
activation of the nuclear factor κB pathway. Interestingly, NE
has been found to activate TLR-4, the surface receptor for
LPS, leading to release of IL-8 by a human embryonic kidney
cell line [32]. This process appears to depend on proteolytic
activity as it was inhibited by phenylmethylsulphonyl
fluoride, a broad spectrum serine protease inhibitor. However,
the exact molecular pathway of TLR-4 activation by NE
needs yet to be addressed and, although NSPs can modulate
the function of integrins, PARs, or TLRs, there isyet no direct
evidence that NSPs actually bind to these classes of cell
surface molecules.
Synergistic effects
Many of the inflammatory pathways modulated by NSPs
are interconnected, so that, hypothetically, NSPs may work
synergistically to accelerate the defense reaction. For
instance, NSPs mediate the release of IL-8 by engaging
several surface receptors such as TLRs, PARs, or integrins
[29, 30, 32]. The bioactivity of IL-8 may then be enhanced
by PR3-mediated truncation of the chemokine N-terminus
[15], leading to increased recruitment of more neutrophils
to the site of inflammation. Moreover, the generation of
active TNFα by PR3 triggers the externalization of further
NSPs by neutrophil granulocytes. Likewise, PGRN inhibits
the release of NSPs by neutrophils [25], thus the degradation
of PGRN by PR3 and NE may drive neutrophils to release
additional NSPs. Furthermore, NSPs often trigger increased
production of ROS by neutrophils, e.g., via the promotion of
integrin clustering or by degrading anti-inflammatory PGRN
[26, 29]. Given that these oxidants inactivate physiological
protease inhibitors [33], NSPs indirectly prolong the time
frame of their actions by promoting ROS production.
Conclusion and outlook
Although NSPs sometimes inactivate certain inflammatory
cytokines and chemokines, the function of NSPs generally
promotes rather than suppresses the inflammatory response.
Especially the relevance of PR3 as a proinflammatory
mediator may have been underestimated in the past. Most
of the target molecules have been identified by in vitro
studies, hence the biological significance of these pathways
often remains to be confirmed using in vivo using
appropriate animal models. The three neutrophil enzymes
CG, NE, and PR3 seem to synergize with each other during
the establishment of an inflammatory milieu. Thus, the
generation of NSP inhibitors specific for all three NSPs
may be a potent inflammation-suppressing drug that could
be used to treat patients with chronic inflammatory
disorders.
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